Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:4/14/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the fourth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

    About MAESTRO-03
    ----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 67 clinical sites who will be administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces 2008 Year End Results
2. BioMS Medical warrant extension
3. BioMS Medical to present at BIO CEO and Investor Conference
4. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
5. BioMS Medical recognized at Scrip Awards 2008
6. BioMS Medical Announces Third Quarter 2008 Results
7. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
11. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , February 17, 2017 ... "Biomarkers Market by Product (Consumables, Service), Type (Safety, ... (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - ... market is projected to reach USD 53.34 Billion ... growing at a CAGR of 13.8% during the ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched ... the agricultural industry. Pilot studies are about to get under way for the framework, ... and 5G innovations. The concept is expected to be transferred eventually to other industries ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
Breaking Biology Technology:
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
Breaking Biology News(10 mins):